This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cooper Companies (COO) Q2 Earnings Top Estimates, '21 View Up
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter 2021 earnings reflect solid segmental performance.
IDEXX (IDXX) Acquires ezyVet to Boost Practice Management Arm
by Zacks Equity Research
The latest acquisition adds to IDEXX's (IDXX) cloud-based practice information management system (PIMS) segment.
PerkinElmer (PKI) Gets COVID-19 Solutions Contract Extension
by Zacks Equity Research
PerkinElmer's (PKI) COVID-19 Lighthouse Laboratory contract extended through March 2022 to align with NHS Test and Trace's testing strategy.
Boston Scientific (BSX) EXALT Gets CE Nod, Endoscopy Arm Grows
by Zacks Equity Research
The European market release of Boston Scientific's (BSX) EXALT Model B Single-Use Bronchoscope will mitigate infection risks associated with reusable imaging scopes.
QIAGEN (QGEN) Launches Expanded Tissue CDx Kit for LUMAKRAS
by Zacks Equity Research
QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.
Integra (IART) Tissue Technologies Rebounds Amid Supply Woe
by Zacks Equity Research
Integra's (IART) CSS segment too reflects a gradual recovery in procedure-based market as well as an improvement in hospital capital spending during the first quarter.
Walgreens' (WBA) New Partnerships Aid, Retail Sales Dip
by Zacks Equity Research
Walgreens Boots' (WBA) response toward combatting the pandemic - conducting COVID-19 tests at various locations and actively participating in vaccinating residents and staff - is impressive.
Illumina (ILMN) Expands NIPT Offering With New Collaboration
by Zacks Equity Research
Illumina's (ILMN) VeriSeq NIPT Solution v2 provides accurate, consistent and scalable end-to-end genome-wide noninvasive prenatal testing.
Myriad Genetics' (MYGN) GeneSight Test Rollout Initiated by IPM
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight testing distribution initiated through IPM will help clinicians and patients assess individual's response to certain medications.
Veeva Systems (VEEV) Q1 Earnings Beat Estimates, '22 View Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both its segments.
Looking for a Growth Stock? Why It is Time to Focus on National Vision (EYE)
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider National Vision (EYE).
New Strong Buy Stocks for May 26th
by Zacks Equity Research
DFIN, EYE, PATK, CCOI, and LL have been added to the Zacks Rank #1 (Strong Buy) List on May 26, 2021
Here's Why You Should Hold on to Exact Sciences (EXAS) Stock
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on solid first-quarter performance and strategic partnerships.
Abbott (ABT) Organic Growth Strong, Pediatric Nutrition Down
by Zacks Equity Research
Within Medical Device, Abbott (ABT) is facing challenging conditions in terms of procedure volume.
Here's Why You Should Hold On to Zimmer Biomet (ZBH) Stock Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on solid first-quarter results and a gradually stabilizing global musculoskeletal market.
Quest Diagnostics (DGX) Base Business Rebounds Amid Price Woe
by Zacks Equity Research
Contributions from acquisitions and Professional Lab Services relationships accelerate base business growth for Quest Diagnostics (DGX).
CVS Health (CVS) Gains From Digitalization, Hurt by Seasonality
by Zacks Equity Research
CVS Health's (CVS) consumer-centric digital strategy is now more relevant in the current environment as people are using technology while staying indoors.
Here's Why You Should Add Phibro (PAHC) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC) on solid third-quarter performance and potential in emerging markets.
Bruker's (BRKR) Research Tools Enable New insight on PACS
by Zacks Equity Research
Bruker's (BRKR) quantitative NMR and MS assay platform together with Australian National Phenome Centre evaluate risk and longitudinal monitoring of post-acute COVID-19 syndrome.
Cardiovascular Systems (CSII) Coronary Arm Grows, Margin Dips
by Zacks Equity Research
Cardiovascular Systems (CSII) is progressing well with its objective to introduce OAS globally.
Cardiovascular Systems (CSII) Coronary OAS Study Data Favorable
by Zacks Equity Research
Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS helps in restoring native vessel compliance, simplify procedural workflow and enhance percutaneous coronary intervention outcomes.
Medtronic (MDT) Reveals Promising Results From Evolut Trial
by Zacks Equity Research
The Low Risk Trial has demonstrated non-inferiority of Medtronic's (MDT) TAVR system over open heart surgery.
LabCorp's (LH) New Bioanalytical Lab to Boost APAC Operation
by Zacks Equity Research
The new laboratory by LabCorp (LH) is set to enable faster data turnaround for early phase trials in Asia-Pacific markets.
Thermo Fisher (TMO) to Boost Cell Therapies With UCSF Deal
by Zacks Equity Research
Thermo Fisher's (TMO) collaboration with UCSF will enable end-to-end solution to accelerate cell therapy development and manufacturing with new facility.
EYE or SRDX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EYE vs. SRDX: Which Stock Is the Better Value Option?